GLP-1 receptor agonist

A compound represented by the following Formula 1, or a pharmaceutically acceptable salt thereof:

• wherein
• A is C6-10 aryl;
• C3-7 cycloalkyl;
• 5- or 6-membered heteroaryl containing one heteroatom selected from N, O, and S;
• 5- or 6-membered heterocycloalkyl containing one heteroatom selected from N, O, and S;
• or 9- or 10-membered fused heteroaryl containing at least one heteroatom selected from N, O, and S,
• B is any one of the following (1) to (5),
• L is —(CH2)n-O—, —O—(CH2)n-, —(CH2)n-NH—, —NH—(CH2)n-, —(CH2)n-N(C1-5 alkyl)-, —N(C1-5 alkyl)-(CH2)n-, —CONH—, or —NHCO—, where n is 1 or 2,
• X is CH or N,
• R1 and R2 are each independently selected from the group consisting of hydrogen, C1-5 alkyl, C1-5 alkoxy, C1-5 haloalkyl, halogen, cyano, and nitro,
• R3 is hydrogen or halogen,
• R4 and R5 are each independently selected from the group consisting of hydrogen, C1-5 alkyl, C1-5 alkoxy, C1-5 haloalkyl, halogen, cyano, and nitro,
• R6 is —(CH2)m—O—(C1-5 alkyl) (where m is 1 or 2);
• C1-5 haloalkyl;
• 5- or 6-membered heteroaryl containing one or two heteroatoms selected from N, O, and S, which is unsubstituted or substituted with C1-5 alkyl;
• or 4- or 5-membered heterocycloalkyl containing one heteroatom selected from N, O, and S, which is unsubstituted or substituted with C1-5 alkyl.